{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-036123","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.564456+00:00","generated_at":"2026-06-17T17:47:58.692176+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cara Therapeutics provides pipeline update; KORSUVA Q4 net sales $2.3M, cash $157M","bullets":["KORSUVA injection net sales: $16.8M Q2, $16.2M Q3, $2.3M Q4 2022; profit-share revenue $8.0M/7.4M/1.1M.","Cash $157M, no debt, 54M shares outstanding; runway into at least 1H 2024.","Oral difelikefalin programs: NDD-CKD Phase 3 topline 2H2024; AD Phase 3 topline 1H2025; NP Phase 2/3 internal readout 2H2024.","KORSUVA Japan approval expected 2H2023; Kapruvia EU launched 2H2022 with $72K Q4 royalty.","TDAPA reimbursement at ASP for min 2 years; positive CMS dialogue on post-TDAPA coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-036123","json":"https://secwatch.observer/filing/0001104659-23-036123.json","markdown":"https://secwatch.observer/filing/0001104659-23-036123.md","text":"https://secwatch.observer/filing/0001104659-23-036123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923036123/0001104659-23-036123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923036123/tm2310376d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:47:58.692176+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}